Hillstar Bio Raises $67 Million Series A Funding to Advance Precision Immunology Therapies for Autoimmune Diseases

Hillstar Bio, a leading biotechnology company, successfully closes a $67 million Series A financing round to advance precision immunology therapies for autoimmune diseases. The funding will support the company's lead TRBV9 program through clinical proof-of-concept studies in axial spondyloarthritis and progression of its broader pipeline.